[Bifunctional biomaterials: An innovative strategy for synergistic bone tumor therapy and bone regeneration].
[OBJECTIVE] To review research progress of bifunctional biomaterials in the treatment of bone tumors and bone defects in recent years, aiming to provide assistance for the further research of bifuncti
APA
Feng W, Chang B, et al. (2026). [Bifunctional biomaterials: An innovative strategy for synergistic bone tumor therapy and bone regeneration].. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 40(4), 681-688. https://doi.org/10.7507/1002-1892.202510084
MLA
Feng W, et al.. "[Bifunctional biomaterials: An innovative strategy for synergistic bone tumor therapy and bone regeneration].." Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, vol. 40, no. 4, 2026, pp. 681-688.
PMID
41981444
Abstract
[OBJECTIVE] To review research progress of bifunctional biomaterials in the treatment of bone tumors and bone defects in recent years, aiming to provide assistance for the further research of bifunctional biomaterials.
[METHODS] A wide range of domestic and international literature on the preparation and properties of novel bifunctional biomaterials in recent years was reviewed, followed by summary and analysis. Carrier-functionalized materials, intrinsically active materials, and immune-engineered materials were summarized respectively, and discussions were conducted from aspects such as anti-tumor effects and controlled drug release.
[RESULTS] Studies have revealed that, unlike traditional biomaterials, the novel bifunctional biomaterials can effectively inhibit the recurrence of bone tumors through precise drug delivery, external field-responsive tumor killing and immunomodulatory anti-tumor effects. Meanwhile, relying on osteoconduction, osteoinduction, and tissue engineering technologies, they promote new bone formation and bone functional reconstruction in bone defect areas.
[CONCLUSION] Novel multifunctional biomaterials can inhibit bone tumor cells and promote new bone formation at the site of bone defects.
[METHODS] A wide range of domestic and international literature on the preparation and properties of novel bifunctional biomaterials in recent years was reviewed, followed by summary and analysis. Carrier-functionalized materials, intrinsically active materials, and immune-engineered materials were summarized respectively, and discussions were conducted from aspects such as anti-tumor effects and controlled drug release.
[RESULTS] Studies have revealed that, unlike traditional biomaterials, the novel bifunctional biomaterials can effectively inhibit the recurrence of bone tumors through precise drug delivery, external field-responsive tumor killing and immunomodulatory anti-tumor effects. Meanwhile, relying on osteoconduction, osteoinduction, and tissue engineering technologies, they promote new bone formation and bone functional reconstruction in bone defect areas.
[CONCLUSION] Novel multifunctional biomaterials can inhibit bone tumor cells and promote new bone formation at the site of bone defects.
MeSH Terms
Bone Regeneration; Biocompatible Materials; Humans; Bone Neoplasms; Tissue Engineering; Drug Delivery Systems; Animals; Bone Substitutes; Tissue Scaffolds; Antineoplastic Agents; Osteogenesis; Drug Carriers
같은 제1저자의 인용 많은 논문 (5)
- Accuracy of Medical Image-Based Deep Learning for Detecting Microvascular Invasion in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis.
- Predictors of one-year adverse outcomes after laparoscopic resection for hepatocellular carcinoma: Development and validation of an early-warning model.
- The oncogenic role of U2AF2/HKDC1 cascade in colorectal cancer by promoting cancer cell glycolysis and malignant phenotypes.
- ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L.
- Urticaria-Like Hypersensitivity Reaction Following Botulinum Toxin Injection: A Case Report of Possible Interaction with β-Lactam Antibiotics.